Biotech IPO Path Often Leads Toward Pharma Partnerships – BIO Venture Forum
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
Replidyne Orapem Antibiotic Likely To Need Additional Trials Before Approval
Replidyne is conducting an additional Phase III trial of its oral beta-lactam antibiotic Orapem in anticipation of an FDA request for additional studies, according to the firm’s initial public offering prospectus.
Licensing In Brief
Shire addition of European rights to Dynepo is key driver of $1.6 bil. TKT merger. Roche’s Xenical to be detailed by GSK. Schering-Plough to out-license U.S. rights to Phase III quinolone antibiotic garenoxacin. Kos plans Teveten and Cardizem LA re-launch in June following purchase/licensing pact with Biovail. More licensing deals in brief
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011